Healthcare
Silexion Therapeutics Ltd.(SLXNW)
Live Price
Offline$0.0271
+7.54% today
1Y Change
-48.57%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- -239.4%
- Dividend Yield
- 0.0%
Coverage: 217 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Silexion Therapeutics Ltd. (SLXNW) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.03 and down 48.6% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -239.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -239.4%, free cash flow -28.6% with operating margin 0.0% and ROIC -250.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLXNW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 19, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -239.4%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 19, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 17, 2026 | -113.0% | +0.0% | +0.0% | +0.0% |
2025 Nov 12, 2025 | +15.3% | -17.3% | -24.6% | -29.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLXNW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLXNW Max Drawdown
-56.47%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLXNW and SPY.
Company Overview
Silexion Therapeutics Ltd.
NASDAQ Global Market
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
- Leadership
- Ilan Hadar
- IPO Date
- Aug 16, 2024
- Employees
- 11
- Street Address
- The Goldyne Savad Institute of Gene Therapy
- Mailing
- Jerusalem, 9112001
- Region
- Jerusalem, IL
- Reporting Currency
- USD
- Investor Line
- 972 2 674 3430
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.4
- Price/Sales
- โ
- Price/Book
- 0.7
Growth
- Revenue
- 0.0%
- EPS
- -239.4%
- Free Cash Flow
- -28.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -387.8%
- ROIC
- -250.7%
Balance Sheet
- Debt/Equity
- 0.18
- Current Ratio
- 2.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.